Sunil Agarwal

TL;DR: A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks and provides evidence of B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.

TL;DR: Both rituximab doses were effective and well tolerated when added to MTX therapy in patients with active rheumatoid arthritis, although intravenous glucocorticoid premedication improved tolerability during the first ritUXimab infusion.

TL;DR: Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamine therapy (licensed doses).

TL;DR: Tocilizumab monotherapy was superior to adalimumabmonotherapy for reduction of signs and symptoms of rheumatoid arthritis in patients for whom methotrexate was deemed inappropriate.

TL;DR: An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy, and events were limited to mild‐to‐moderate infusion‐associated events, which tended to decrease with subsequent infusions.